Theravance Biopharma (NASDAQ:TBPH – Get Free Report) and Nexentis Technologies (NASDAQ:NXTS – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Theravance Biopharma and Nexentis Technologies, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Theravance Biopharma | 0 | 7 | 0 | 0 | 2.00 |
| Nexentis Technologies | 1 | 0 | 0 | 0 | 1.00 |
Theravance Biopharma currently has a consensus target price of $19.00, indicating a potential upside of 11.57%. Given Theravance Biopharma’s stronger consensus rating and higher possible upside, analysts clearly believe Theravance Biopharma is more favorable than Nexentis Technologies.
Profitability
This table compares Theravance Biopharma and Nexentis Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Theravance Biopharma | 51.58% | -0.77% | -0.46% |
| Nexentis Technologies | N/A | -304.79% | -178.91% |
Risk & Volatility
Theravance Biopharma has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Comparatively, Nexentis Technologies has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500.
Insider and Institutional Ownership
99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 61.2% of Nexentis Technologies shares are held by institutional investors. 7.6% of Theravance Biopharma shares are held by insiders. Comparatively, 6.5% of Nexentis Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Theravance Biopharma and Nexentis Technologies”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Theravance Biopharma | $104.31 million | 8.48 | $105.89 million | $1.01 | 16.86 |
| Nexentis Technologies | $210,000.00 | 3.18 | -$4.00 million | ($96.07) | -0.02 |
Theravance Biopharma has higher revenue and earnings than Nexentis Technologies. Nexentis Technologies is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
Theravance Biopharma beats Nexentis Technologies on 12 of the 13 factors compared between the two stocks.
About Theravance Biopharma
Theravance Biopharma is a biopharmaceutical company focused on developing and commercializing medicines. Its marketed product, YUPELRI (revefenacin), is a once-daily nebulized treatment for the maintenance of chronic obstructive pulmonary disease (COPD) in adults. In the United States, the product is commercialized through a collaboration with Viatris. The company was established as an independent business following its separation from Theravance, Inc. in 2014. Its research and development work has included therapies for respiratory and other serious conditions.
About Nexentis Technologies
N2OFF, Inc., an agri-food tech company, engages in the development and sale of eco-friendly green solutions for the food industry to enhance food safety and shelf life of fresh produce. Its products are based on proprietary blend of food acids combined with various oxidizing agent-based sanitizers and low concentrated fungicides for cleaning, sanitizing, and controlling pathogens on fresh produce that are safer for human consumption and extend their shelf life by reducing their decay. The company’s products include SavePROTECT or PeroStar, a processing aid for post-harvest application that is added to fruit and vegetable wash water; and SF3HS and SF3H, a post-harvest cleaning and sanitizing solution to control plant and foodborne pathogens.
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
